Inclusion Criteria:

- Recurrent epithelial ovarian or primary peritoneal carcinoma

- Measurable disease

- At lease 1 target lesion to assess response by RECIST

- GOG performance status 0 or 1

- Recovery from effects of recent surgery, radiotherapy or chemotherapy, must
discontinue hormonal therapy

- Must have had 1 prior platinum based chemotherapeutic regimen for management of
primary disease

- Must have had 1 prior regimen containing a taxane compound

Exclusion Criteria:

- Prior therapy with pemetrexed or bevacizumab

- Serious, non-healing wound, ulcer or bone fracture

- Clinically significant cardiovascular disease

- Active bleeding or pathogenic conditions that carry high risk of bleeding, such as
known bleeding disorder, coagulopathy, or tumor involving major - vessels

- Ascites or other third space fluid which cannot be controlled by drainage

- Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
prior to day 1 or anticipation of need for major surgical procedure during course of
study

- History or evidence upon physical exam of CNS disease, including primary brain tumor,
brain mets, seizure not controlled with standard medical therapy, history of
CVA/stroke/TIA, or subarachnoid hemorrhage within 6 mos. of day 1

- Proteinuria

- History of abdominal fistula, GI perforation or intra-abdominal abscess within 6 mo.

- Partial or complete small or large bowel obstruction within 3 mo.

- Life expectancy less than 12 weeks